Maria Scarselli obtained her PhD in Biotechnology at the University of Siena in 1995 with a thesis on the design and structural characterization of protein epitopes. Between 1996 and 2005, she focused her academic research activity on NMR structural characterization of proteins and immuno-active peptides and the design of peptide mimetics of bacterial and viral antigens. In 1998, she collaborated with Chiron Vaccines on the MenB vaccine antigen identification through the Reverse Vaccinology approach that led to the Bexsero vaccine. Since 2005, she has joined Novartis Vaccines, working on bacterial antigen discovery and optimization projects. In 2016, she joined Glaxo-Smith Lyne, and in 2019, MS was appointed as Antigen Design Scientific Leader.
Maria Scarselli obtained her PhD in Biotechnology at the University of Siena in 1995 with a thesis on the design and structural characterization of protein epitopes. Between 1996 and 2005, she focused her academic research activity on NMR structural characterization of proteins and immuno-active peptides and the design of peptide mimetics of bacterial and viral antigens. In 1998, she collaborated with Chiron Vaccines on the MenB vaccine antigen identification through the Reverse Vaccinology approach that led to the Bexsero vaccine. Since 2005, she has joined Novartis Vaccines, working on bacterial antigen discovery and optimization projects. In 2016, she joined Glaxo-Smith Lyne, and in 2019, MS was appointed as Antigen Design Scientific Leader.